近视的炎症反应机制及抗炎治疗的研究进展  

Research Progress on the Inflammatory Response Mechanism and Anti-Inflammatory Treatment of Myopia

作　　者：薛智鹏 左韬[2] 赵磊[2] 张鑫鑫 杨凡 Zhipeng Xue;Tao Zuo;Lei Zhao;Xinxin Zhang;Fan Yang(Liaoning University of Traditional Chinese Medicine,Shenyang 110847,China;Department of Ophthalmology,the Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110034,China)

机构地区：[1]辽宁中医药大学,沈阳110847 [2]辽宁中医药大学附属第二医院眼科,沈阳110034

出　　处：《中华眼视光学与视觉科学杂志》2024年第6期476-480,共5页Chinese Journal Of Optometry Ophthalmology And Visual Science

基　　金：辽宁省科学技术计划项目(2022-BS-069);辽宁省教育厅基本科研项目(LJKQZ20222404)

摘　　要：近视是全球性重大卫生问题,中国更是近视大国,发病率和总人数居世界首位。目前认为炎症反应在近视发展过程中有重要作用。抗氧化、抗新生血管及巩膜交联术等方法均可通过抑制炎症发挥治疗近视的作用,从而有效地控制近视及其并发症,因此调控炎症也是新药研发的一个重要方向。现笔者对炎症反应在近视发展过程中的作用及其相关药物的研究进展进行综述,以期为治疗与防控近视提供新的思路。Myopia is a major global health problem,and China is a major country of myopia,with the incidence and total number of people ranking first in the world.It is currently believed that inflammatory responses have an important role in the development of myopia.Antioxidant,anti-neovascularization and scleral crosslinking can treat myopia by inhibiting inflammation to effectively control myopia and its complications,so the regulation of inflammation is also an important direction of new drug research and development.The author now reviews the role of inflammatory reaction in the development of myopia and the research progress of related drugs,in order to provide new ideas for the treatment and prevention and control of myopia diseases.

关 键 词：近视 炎症反应 炎症因子 白细胞介素 抗炎治疗 

分 类 号：R778.11[医药卫生—眼科]